Dianthus Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
52W Range
87thpctl
Volume
0.42×avg
Market Cap
5.92BUSD
P/E Ratio
-814.2TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Dianthus Therapeutics, Inc.
DNTHNASDAQ·USD·Closed
Dianthus Therapeutics, Inc.
DNTHNASDAQ·USD·Closed
$105.84
−5.11%
$105.84
−$5.70 (5.11%)
52W Range
87thpctl
Volume
0.42×avg
Mkt Cap
5.92BUSD
P/E
-814.2TTM
Div Yield
–ann
DNTH: Dianthus Therapeutics, Inc. Stock Analysis | finqOS
